Phaseline

Companies › Napo Therapeutics

Napo Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Gastroenterology; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Crofelemer
Cystic fibrosis transmembrane conductance regulator inhibitor; Anoctamin-1 blocker
CFTR, ANO1Phase 2Short Bowel SyndromeMar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06904872CrofelemerPhase 2Short Bowel SyndromeGastroenterologyMar 2027

Targets

CFTR (1) ANO1 (1)

Companies with the same targets

Vertex Pharmaceuticals Napo Pharmaceuticals 4D Molecular Therapeutics ReCode Therapeutics Qanatpharma Krystal Biotech Boehringer Ingelheim Arcturus Therapeutics

Companies built like this

Dr. Falk Pharma Panafina NorthSea Therapeutics TRYP Therapeutics Healthgen Biotechnology

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.